Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9636719 | 0.78 | ALDH1A1 (0.55) | ALDH1A1POLBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3593084 | 0.78 | ALDH1A1 (0.55) | ALDH1A1POLBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4700879 | 0.78 | CYP2C19 (0.42) | ALDH1A1CYP2C19ELANEHPGD | |
| SCHEMBL4698178 | 0.78 | CYP2C19 (0.42) | ALDH1A1CYP2C19ELANEHPGD | |
| SCHEMBL4179162 | 0.77 | ALDH1A1 (0.44) | ALDH1A1POLBELANEHPGD | |
| SCHEMBL6184918 | 0.77 | ALDH1A1 (0.44) | ALDH1A1POLBELANEHPGD | |
| SCHEMBL3563705 | 0.76 | MT-CO2 (0.44) | ALDH1A1POLBELANEHPGD | |
| SCHEMBL444081 | 0.75 | SLC18A3 (0.41) | ALDH1A1F2ELANE | |
| SCHEMBL444082 | 0.75 | SLC18A3 (0.41) | ALDH1A1F2ELANE | |
| SCHEMBL11421470 | 0.75 | HPGD (0.46) | F2ELANEHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662854-B2 | HIF hydroxylase inhibitors | ISIS INNOVATION LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-7638295-B2 | Identifying agent which modulates 2-oxoglutarate dependent oxygenase; ankyrin substrate; hypoxia-inducible factor; thalassemia | ISIS INNOVATION LIMITED (GB) | 2009-12-29 | — | — | US | disclosed |
| EP-2065366-A2 | HIF hydroxylase inhibitors | ISIS Innovation Limited (GB) | 2009-06-03 | — | — | EP | disclosed |
| US-20080227848-A1 | Assays | ISIS INNOVATION LIMITED (GB) | 2008-09-18 | — | — | US | disclosed |
| CN-101199512-A | Hif hydroxylase inhibitors | ISIS INNOVATION (GB) | 2008-06-18 | — | — | CN | disclosed |
| CN-101199501-A | HIF hydroxylase inhibitors | ISIS INNOVATION (GB) | 2008-06-18 | — | — | CN | disclosed |
| CN-101199502-A | Hif hydroxylase inhibitors | ISIS INNOVATION (GB) | 2008-06-18 | — | — | CN | disclosed |
| CN-101199503-A | Hif hydroxylase inhibitors | ISIS INNOVATION (GB) | 2008-06-18 | — | — | CN | disclosed |
| CN-101199537-A | Hif hydroxylase inhibitors | ISIS INNOVATION (GB) | 2008-06-18 | — | — | CN | disclosed |
| US-20070066576-A1 | HIF hydroxylase inhibitors | ISIS INNOVATION LIMITED (GB) | 2007-03-22 | — | — | US | disclosed |
| EP-1733030-A2 | ASSAYS FOR IDENTIFYING MODULATORS OF THE HYDROXYLATION OF ANKYRIN REPEAT PROTEINS BY 2-OXOGLUTARATE DEPENDENT OXYGENASE AND METHODS OF USING THE SAME | ISIS INNOVATION LIMITED (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20050227948-A1 | Hif hydroxylase inhibitors | ISIS INNOVATION LIMITED (GB) | 2005-10-13 | — | — | US | disclosed |
| WO-2005093411-A2 | ASSAYS FOR IDENTIFYING MODULATORS OF THE HYDROXYLATION OF ANKYRIN REPEAT PROTEINS BY 2-OXOGLUTARATE DEPENDENT OXIGENASE AND METHODS OF USING THE SAME | ISIS INNOVATION LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| EP-1485347-A2 | HIF HYDROXYLASE INHIBITORS | ISIS INNOVATION LIMITED (GB) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003080566-A2 | HIF HYDROXYLASE INHIBITORS | ISIS INNOVATION LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227948-A1 | Hif hydroxylase inhibitors | HIF1AN, HIF1A, EGLN3 | ALDH1A1 163/4885F2 3774/4885POLB 1882/4885 |
| US-20070066576-A1 | HIF hydroxylase inhibitors | HIF1AN, HIF1A, EGLN3 | ALDH1A1 163/4885F2 3774/4885POLB 1882/4885 |
| US-20080227848-A1 | Assays | OGDH, HOGA1, OXGR1 | ALDH1A1 1624/4885F2 2794/4885POLB 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.